Pharma giant Eli Lilly is setting its sights on a 2027 regulatory submission for its promising next-generation obesity drug, retatrutide. This announcement comes on the heels of two successful Phase 3 clinical trials, bolstering the company's confidence in the drug's potential. While Lilly had previously indicated an earlier filing as early as this year for the weekly injection, they now state a need for additional time to meticulously gather and verify the manufacturing and quality-control data mandated by regulatory bodies.
Retatrutide, a drug that operates on a novel mechanism and appears to surpass the effectiveness of current weight-loss medications, has demonstrated significant clinical benefits. In two separate Phase 3 trials, the drug facilitated considerable weight reduction and enhanced key blood sugar level markers in adults grappling with obesity complicated by Type 2 diabetes or established cardiovascular disease.
According to Kenneth Custer, president of Lilly Cardiometabolic Health, the company possesses sufficient data to pursue global approval for retatrutide across multiple indications, including obesity, knee osteoarthritis pain, and obstructive sleep apnea.
One trial showcased an average weight loss of 20.8% (approximately 50 pounds) over 80 weeks for adults with obesity and diabetes, a demographic that often faces challenges in weight management. In a parallel study involving individuals with severe obesity and cardiovascular disease (with or without diabetes), participants achieved an average weight loss of 22.6% (about 55.8 pounds) over the same period. Lilly further noted that retatrutide significantly improved cardiovascular risk factors in these patients.
The safety profile observed for retatrutide remained consistent with previous studies, with common side effects including diarrhea, nausea, and constipation – symptoms also associated with other drugs in the GLP-1 class. The drug has now garnered positive results from five late-stage trials.
Lilly positions retatrutide as the next cornerstone of its obesity treatment portfolio, following the success of its injection Zepbound and the recently launched pill, Foundayo. Analysts from TD Cowen project that retatrutide could generate approximately $3.8 billion in sales by 2030. The development of retatrutide is also crucial for Eli Lilly's strategy to maintain its market leadership against competitor Novo Nordisk in the rapidly expanding multi-billion dollar weight loss and diabetes drug market.
Nicknamed the "triple G" drug, retatrutide distinguishes itself by targeting GLP-1, GIP, and glucagon hormones simultaneously, unlike existing treatments that focus on one or two. This multi-hormonal approach is believed to yield more potent effects on appetite regulation and satiety.
For context, tirzepatide (the active ingredient in Zepbound) mimics GLP-1 and GIP, while Novo Nordisk's semaglutide (the active ingredient in Wegovy) targets only GLP-1.
